Hepion pharmaceuticals to deliver updates on ongoing phase 2 nash clinical program with rencofilstat at 6th global nash congress

Edison, n.j., march 02, 2023 (globe newswire) -- hepion pharmaceuticals, inc. (nasdaq:hepa), a clinical stage biopharmaceutical company focused on artificial intelligence (“ai”)-driven therapeutic drug development for the treatment of fibrotic diseases, including non-alcoholic steatohepatitis (“nash”), hepatocellular carcinoma (“hcc”), and other chronic diseases, announces that its chief medical officer, todd hobbs, md, will be presenting “rencofilstat (crv431): update on nash clinical program,” on friday, march 3rd at the 6th global nash congress held in london, england.
HEPA Ratings Summary
HEPA Quant Ranking